

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ALVOTECH USA INC. and ALVOTECH HF,
Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Case: PGR2025-00085
U.S. Patent No. 12,168,036

PATENT OWNER'S UPDATED LIST OF EXHIBITS
(as of July 13, 2026)

Exhibit	Description	Filed
2001	Excerpts from the File History of U.S. Appl. No. 17/384,070	X
2002	US 2018/0326126 (“Fiedler ’126”)	X
2003	Australian Dep’t of Health & Human Aging, Australian Public Assessment Report for Aflibercept (July 2012) (“AusPAR”)	X
2004	Ameya U. Borwankar et al., <i>Viscosity Reduction of a Concentrated Monoclonal Antibody with Arginine.HCl and Arginine.Glutamate</i> , 55 Ind. Eng. Chem. Rsch. 11225 (2016) (“Borwankar”)	X
2005	Neal Whitaker et al., <i>A Formulation Development Approach to Identify and Select Stable Ultra–High-Concentration Monoclonal Antibody Formulations with Reduced Viscosities</i> , 106 J. Pharmaceutical Scis. 3230 (2017) (“Whitaker”)	X
2006	Ameya U. Borwankar et al., <i>Viscosity Reduction of a Concentrated Monoclonal Antibody with Arginine.HCl and Arginine.Glutamate: Supplementary Information</i> , 55 Ind. Eng. Chem. Rsch. 11225 (2016) (“Borwankar SI”)	X
2007	Eylea HD® Highlights of Prescribing Information (Oct. 2024)	X
2008	AbbVie, Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar Pegol, AbbVie News Center (June 26, 2020), https://news.abbvie.com/2020-06-26-Allergan-an-AbbVie-Company-and-Molecular-Partners-Receive-Complete-Response-Letter-from-FDA-on-Biologics-License-Application-for-Abicipar-pegol (“AbbVie Press Release”)	X

Exhibit	Description	Filed
2009	Rod McNeil, <i>Advances and Developments in Medical Retina</i> , 25 Eye News 1 (2019) (“McNeil”)	X
2010	Rehan M. Hussain & Thomas A. Ciulla, <i>Emerging Vascular Endothelial Growth Factor Antagonists to Treat Neovascular Age-Related Macular Degeneration</i> , 22 Expert Op. Emerging Drugs 235 (2017) (“Hussain”)	X
2011	Angus Liu, <i>Novartis Calls off 3 Beovu Trials Testing More Frequent Dosing on Concerns of Vision-Threatening Side Effect</i> , FiercePharma (June 1, 2021) (“Liu 2021”)	X
2012	Beovu Label (2024)	X
2013	Philip J. Rosenfeld & David J. Browning, <i>Editorial: Is This a 737 Max Moment for Brocizumab?</i> , 216 Am. J. Ophthalmology A7 (2020) (“Rosenfeld”)	X
2014	J. Gaudreault et al., <i>Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) After a Single Intravitreal Administration</i> , 46 Invest. Ophthalmol Vis. Sci. 726 (2005) (“Gaudreault”)	X
2015	Public Trial Transcript Excerpts, <i>Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.</i> , No. 22-cv-61 (N.D.W. Va.)	X
2016	Wang, <i>Protein Aggregation and Its Inhibition in Biopharmaceutics</i> , 289 Int. J. Pharm. 1 (2005) (“Wang 2005”)	X
2017	Wang, <i>Instability, Stabilization, and Formulation of Liquid Protein Pharmaceuticals</i> , 1856 Int. J. Pharm. 129 (1999) (“Wang 1999”)	X

Exhibit	Description	Filed
2018	Philip J. Rosenfeld et al., <i>Maximum Tolerated Dose of a Humanized Anti-Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration</i> , 112 Ophthalmology 1048 (2005) (“Rosenfeld 2005”)	X
2019	U.S. Patent Application Publication No. 2004/0197324 (“Liu 2004”)	X
2020	U.S. Patent No. 7,087,411 (“Daly”)	X
2021	WO 2006/138181 (“Gokarn”)	X
2022	Rahul N. Khurana et al., <i>Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration</i> , 128 Ophthalmology 1027 (2021) (“Khurana 2021”)	X
2023	James A. Dixon et al., <i>VEGF Trap-Eye for the Treatment of Neovascular Age-Related Macular Degeneration</i> , 18 Expert Opinion Investigational Drugs 1573 (2009) (“Dixon 2009”)	X
2024	Pravin U. Dugel et al., <i>HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration</i> , 128 Ophthalmology 89 (2021) (“Dugel”)	X
2025	John S.Y. Park & David R. Chow, <i>Clinical Primer on Eylea HD: Review of the Current Data</i> , Retina Specialist (Apr. 13, 2024), https://www.retina-specialist.com/article/clinical-primer-on-eylea-hd-review-of-the-current-data (“Park”)	X
2026	Vabysmo Label 2024 (“Vabysmo Label”)	X

Exhibit	Description	Filed
2027	Jonas L. Fast et al., <i>Physical Instability of a Therapeutic Fc Fusion Protein: Domain Contributions to Conformational and Colloidal Stability</i> , 48 Biochemistry 11724 (2009) (“Fast”)	X
2028	Zaltrap Label 2023 (“Zaltrap Label”)	X
2029	Michael Thomas, <i>Comparative Effectiveness of Aflibercept for the Treatment of Patients with Neovascular Age-related Macular Degeneration</i> , 7 Clinical Ophthalmology 495 (2013) (“Thomas”)	X
2030	Alvotech, Report of Foreign Private Issuer (Form 6-K) (June 23, 2025) (“Alvotech Press Release”)	X
2031	Molecular Partners, Molecular Partners to Regain Global Rights to Abicipar, Molecular Partners News Release Details (Aug. 8, 2021) https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-regain-global-rights-abicipar (“Molecular Partners Press Release”)	X
2032	Novartis, <i>Novartis Reports One Year Results of Phase III MERLIN Study Evaluating Beovu® Every Four Week Dosing and Provides Update on Beovu Clinical Program</i> , Novartis Media Releases (May 28, 2021) https://www.novartis.com/news/media-releases/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program (“Novartis Press Release”)	X
2033	U.S. Patent Application Publication No. 2023/0416353	X
2034	WO 2014/009465	X
2035	U.S. Food & Drug Admin., Eylea HD Approval Letter (Aug. 18, 2023) (“Eylea HD FDA Approval Letter”)	X

Exhibit	Description	Filed
2036	Gerard A. Rodrigues, <i>Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability</i> , 59 <i>Investigative Ophthalmology & Visual Science</i> 5836 (2018) (“Rodrigues 2018”)	X
2037	Declaration of K. Kayali	X
2038	Petition for Post Grant Review of United States Patent No. 12,168,036, Paper No. 2, PGR2025-00085	X
2039	Robert J. Falconer, <i>Advances in Liquid Formulations of Parenteral Therapeutic Proteins</i> , 37 <i>Biotechnology Advances</i> 1 (2019) (“Falconer 2019”)	X
2040	18th Annual Conference, Bioprocessing Network 2025, Conference Schedule (“Conference Schedule”)	X
2041	D’Amico article, <i>American Journal of Ophthalmology</i> , August, 1985	X
2042	Talamo article, <i>American Journal of Ophthalmology</i> , December, 1985	X
2043	Oum article, <i>Graefe’s Archive for Clinical and Experimental Ophthalmology</i> 1992	X
2044	Sakarya article, <i>European Journal Ophthalmology</i> 2010	X
2045	Macugen Highlights of Prescribing Information, Bates ALVOTECH 1048	X
2046	Deposition Transcript of Dr. Robert J. Falconer (May 27, 2026)	X
2047	U.S. Patent No. 7,396,664	X

Exhibit	Description	Filed
2048	U.S. Patent No. 7,354,579	X
2049	H. Abe, <i>Role of Histidine-Related Compounds as Intracellular Proton Buffering Constituents in Vertebrate Muscle</i> , 65 Biochemistry (Moscow) 757 (2000)	X
2050	U.S. Patent App. Pub. 2011/0027292	X
2051	Declaration of Bernhardt Trout (June 19, 2026)	X
2052	Declaration of Neil Bressler (June 19, 2026)	X
2053	Deposition Transcript of Dr. Donald J. D’Amico (June 2, 2026)	X
2054	Excerpts from File History of U.S. Patent Application No. 16/409,631	X
2055	Excerpts from the Oxford Dictionary of Biochemistry and Molecular Biology (2d ed. 2000)	X
2056	Francis A. Carey & Robert M. Giuliano, Organic Chemistry, Chapter 25 (8th ed. 2011)	X
2057	Excerpts from the Handbook of Pharmaceutical Excipients (4th ed. 2003) (“HPE”)	X
2058	Aruffo, <i>Immunoglobulin Fusion Proteins</i> , in Antibody Fusion Proteins 221 (Chamow & Ashkenazi eds., 1999) (“Aruffo 1999”)	X
2059	Avastin® Prescribing Information (2004) (“Avastin PI”)	X
2060	Bogard et al., <i>Practical Considerations in the Production, Purification, and Formulation of Monoclonal Antibodies for Immunoscintigraphy and Immunotherapy</i> , 19 Seminars in Nuclear Med. 202 (1989) (“Bogard 1989”)	X

Exhibit	Description	Filed
2061	Chang et al., <i>Practical Approaches to Protein Formulation Development</i> , in Rational Design of Stable Protein Formulations (J.F. Carpenter & M.C. Manning eds., 2002) (“Chang 2002”)	X
2062	Chi et al., <i>Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation</i> , 20 Pharm. Res. 1325 (2003) (“Chi 2003”)	X
2063	S. Duvvuri et al., <i>Drug Delivery to the Retina: Challenges and Opportunities</i> , 3 Expert Op. Biological Therapy 45 (2003) (“Duvvuri 2003”)	X
2064	Eylea® Prescribing Information (2011) (“Eylea PI 2011”)	X
2065	D. Ghate & H.F. Edelhauser, <i>Ocular Drug Delivery</i> , 3 Expert Op. Biological Therapy 275 (2006) (“Ghate 2006”)	X
2066	Lucentis® Prescribing Information (2006) (“Lucentis PI 2006”)	X
2067	Macugen® Prescribing Information (2004) (“Macugen PI 2004”)	X
2068	R.P.A. Manzano et al., <i>Testing Intravitreal Toxicity of Bevacizumab (Avastin)</i> , 26 Retina 257 (2006) (“Manzano 2006”)	X
2069	Moroney et al., <i>Aflibercept in Epithelial Ovarian Carcinoma</i> , 5 Future Oncol. 591 (2009) (“Moroney 2009”)	X
2070	M. Nagpal et al., <i>A Comparative Debate on the Various Anti-Vascular Endothelial Growth Factor Drugs</i> , 55 Indian J. Ophthalmology 437 (2007) (“Nagpal”)	X
2071	Int’l Patent Publication No. WO2005/102303 (2005) (“Peyman”)	X

Exhibit	Description	Filed
2072	Shukla et al., <i>Downstream Processing of Fc-Fusion Proteins</i> , in <i>Therapeutic Fc-Fusion Proteins</i> 97 (Chamow et al. eds., 2014) (“Shukla 2014”)	X
2073	Souillac, <i>Biophysical Characterization of Insoluble Aggregates of a Multi-Domain Protein: An Insight into the Role of the Various Domains</i> , 94 J. Pharm. Sci. 2066 (2005) (“Souillac 2005”)	X
2074	C.A. Stein & D. Castanotto, <i>FDA-Approved Oligonucleotide Therapies in 2017</i> , 25 Molecular Therapy 1069 (2017) (“Stein”)	X
2075	Wang et al., <i>Antibody Structure, Instability, and Formulation</i> , 96 J. Pharm. Sci. 1 (2007) (“Wang 2007”)	X
2076	Winter & Milstein, <i>Man-made Antibodies</i> , 349 Nature 293 (1991) (“Winter 1991”)	X
2077	Wurm et al., <i>Optimizing Production and Recovery of Immunoadhesins</i> , in <i>Antibody Fusion Proteins</i> 281 (Chamow & Ashkenazi eds., 1999) (“Wurm 1999”)	X
2078	Liu et al., <i>Reversible Self-Association Increases the Viscosity of a Concentrated Monoclonal Antibody in Aqueous Solution</i> , 94 J. Pharm. Sci. 1928 (2005) (“Liu 2005”)	X
2079	Shire et al., <i>Challenges in the Development of High Protein Concentration Formulations</i> , 93 J. Pharm. Sci. 1390 (2004) (“Shire 2004”)	X
2080	Neeraj J. Agrawal et al., <i>Computational Tool for the Early Screening of Monoclonal Antibodies for Their Viscosities</i> , 8 mAbs 43 (2016) (“Agrawal”)	X
2081	Merriam-Webster’s Medical Desk Dictionary (2002) (“Merriam-Webster”)	X

Exhibit	Description	Filed
2082	Halvor N. Christensen, <i>Proteins as Buffers</i> , Ann. 133 N.Y. Acad. Sci. 34 (1966) (“Christensen”)	X
2083	Y. Nozaki & C. Tanford, <i>Examination of Titration Behavior</i> , 11 Methods in Enzymology 715 (1967) (“Nozaki”)	X
2084	J. Wyman, <i>An Analysis of the Titration Data of Oxyhemoglobin of the Horse by a Thermal Method</i> , 127 J. Biol. Chem. 1 (1939) (“Wyman”)	X
2085	Andrew A. Moshfeghi, <i>Safety of Intravitreal Anti-VEGF Agents</i> , Review of Ophthalmology (Nov. 11, 2014), https://www.reviewofophthalmology.com/article/safety-of-intravitreal-antivegf-agents	X
2086	Joseph J. Tseng et al., <i>Sustained Increased Intraocular Pressure Related to Intravitreal Antivascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration</i> , 21 J. Glaucoma 241 (2012)	X
2087	Judy E. Kim et al., <i>Short-Term Intraocular Pressure Changes Immediately After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents</i> , 146 Am. J. Ophthalmol. 930 (2008).	X
2088	Evangelos S. Gragoudas et al., <i>Pegaptanib for Neovascular Age-Related Macular Degeneration</i> , 351 New Eng. J. Med. 2805 (2004)	X
2089	David M. Brown et al., <i>Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-Related Macular Degeneration</i> , 118 Ophthalmology 1089 (2011)	X

Exhibit	Description	Filed
2090	Jeffrey S. Heier et al., <i>Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration</i> , 119 Ophthalmology 2537 (2012)	X
2091	Christophe Le Tourneau et al., <i>Dose Escalation Methods in Phase I Cancer Clinical Trials</i> , 101 J. Nat'l Cancer Inst. 708 (2009)	X
2092	Jeffrey R. Sachs et al., <i>Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example</i> , 22 Clinical Cancer Rsch. 1318 (2016)	X
2093	RESERVED	
2094	Jiunn H. Lin, <i>Species Similarities and Differences in Pharmacokinetics</i> , 23 Drug Metabolism & Disposition 1008 (1995)	X
2095	Frank G. Holz et al., <i>Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials</i> , 136 JAMA Ophthalmol. 666 (2018)	X
2096	Neil M. Bressler et al., <i>Intraocular Pressure Outcomes After Lampalizumab Injections in Patients with Geographic Atrophy</i> , 142 JAMA Ophthalmol. 772 (2024)	X
2097	LabChem Inc., Material Safety Data Sheet: Congo Red (CAS No. 573-58-0)	X
2098	Agar Scientific Ltd., Safety Data Sheet: Congo Red (C.I. 22120)	X
2099	Santa Cruz Biotechnology, Safety Data Sheet: Amaranth (SC-214532)	X

Exhibit	Description	Filed
2100	Eduardo B. Rodrigues et al., <i>Preclinical Investigation of the Retinal Biocompatibility of Six Novel Vital Dyes for Chromovitrectomy</i> , 29 Retina 497 (2009)	X
2101	Carolina Biological Supply Co., Safety Data Sheet: Crystal Violet (CAS No. 548-62-9)	X
2102	Ellen Kurek, <i>Conflicting Evidence over Stroke Risk from AMD Drug</i> , Pharmacy Times, available at https://www.pharmacytimes.com/view/conflicting-evidence-over-stroke-risk-from-amd-drug (last visited June 12, 2026)	X
2103	Rajendra S. Apte et al., <i>Pegaptanib 1-Year Systemic Safety Results from a Safety-Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular Degeneration</i> , 114 Ophthalmology 1702 (2007)	X
2104	Bevacizumab (Avastin®) Label 2017 (Avastin Label)	X
2105	James A. Hanley & Abby Lippman-Hand, <i>If Nothing Goes Wrong, Is Everything All Right? Interpreting Zero Numerators</i> , 249 JAMA 1743 (1983)	X
2106	Mehdi Modarreszadeh et al., <i>Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-Related Macular Degeneration</i> , 3 J. Ophthalmic & Vision Res. 102 (2008)	X
2107	Deepika Malik et al., <i>Safety Profiles of Anti-VEGF Drugs: Bevacizumab, Ranibizumab, Aflibercept and Ziv-Aflibercept on Human Retinal Pigment Epithelium Cells in Culture</i> , 98 Brit. J. Ophthalmol. i11 (2014)	X
2108	Robert L. Avery et al., <i>Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab</i> , 37 Retina 1847 (2017)	X

Exhibit	Description	Filed
2109	U.S. Food & Drug Admin., <i>Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers</i> (July 2005)	X
2110	Brandon G. Busbee et al., <i>Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration</i> , 120 <i>Ophthalmology</i> 1046 (2013)	X
2111	U.S. Food & Drug Admin., <i>Postmarketing Adverse Event Reporting Compliance Program</i> , https://www.fda.gov/drugs/surveillance-post-drug-approval-activities/postmarketing-adverse-event-reporting-compliance-program (last visited June 16, 2026)	X
2112	U.S. Food & Drug Admin., <i>Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients</i> (May 2005)	X
2113	Sophie Postel-Vinay et al., <i>Towards New Methods for the Determination of Dose Limiting Toxicities and the Assessment of the Recommended Dose for Further Studies of Molecularly Targeted Agents—Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted Therapies, an European Organisation for Research and Treatment of Cancer-Led Study</i> , 50 <i>Eur. J. Cancer</i> 2040 (2014)	X
2114	RESERVED	
2115	V. Burckbuchler et al., <i>Rheological and Syringeability Properties of Highly Concentrated Human Polyclonal Immunoglobulin Solutions</i> , 76 <i>Eur. J. Pharmaceutics & Biopharmaceutics</i> 351 (2010)	X

Exhibit	Description	Filed
2116	Francesco Cilurzo et al., <i>Injectability Evaluation: An Open Issue</i> , 12 AAPS PharmSciTech 604 (2011)	X
2117	<i>Regeneron Pharm., Inc. v. Mylan Pharm. Inc.</i> , 714 F. Supp. 3d 652 (N.D.W. Va. 2024) (“Mylan”)	X
2118	Jeffrey S. Heier et al., <i>The 1-Year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-Needed After 12-Week Fixed Dosing</i> , 118 Ophthalmology 1098 (2011)	X
2119	RESERVED	
2120	Claudine E. Pang et al., <i>Association Between Needle Size, Postinjection Reflux, and Intraocular Pressure Spikes After Intravitreal Injections</i> , 35 Retina 1401 (2015)	X
2121	Vinicius S. De Stefano et al., <i>Experimental Investigation of Needles, Syringes and Techniques for Intravitreal Injections</i> , 39 Clinical & Experimental Ophthalmology 236 (2011)	X
2122	Jean-Pierre Hubschman et al., <i>Experimental Model of Intravitreal Injection Techniques</i> , 30 Retina 167 (2010)	X
2123	Hussein Hollands, et al., <i>Short-term Intraocular Pressure Changes after Intravitreal Injection of Bevacizumab</i> , 42 Can J. Ophthalmology 807 (2007)	X
2124	Daniel Y. Choi, <i>Sustained Elevated Intraocular Pressures After Intravitreal Injections of Bevacizumab, Ranibizumab, and Pegaptinib</i> , 31(6) Retina 1028 (2011)	X
2125	Third-Party Confidential Transcript	X
2126	Roche, <i>Angiogenesis Highlights</i> (Feb. 16, 2021)	X

Exhibit	Description	Filed
2127	U.S. Food & Drug Admin., <i>Inactive Ingredients in Approved Drug Products Search: Frequently Asked Questions</i> , https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-approved-drug-products-search-frequently-asked-questions (last visited June 17, 2026) (“Inactive Ingredient FAQ”)	X
2128	Mohammed Gabr Kassem, <i>Sunitinib Malate</i> , 37 Profiles of Drug Substances, Excipients, and Related Methodology 363 (2021) (“Kassem”)	X
2129	Xue-qing Wang, <i>Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat</i> , 419 Int’l J. of Pharmaceutics 339 (2011) (“Wang 2011”)	X
2130	<i>Clinical & Pharmacology & Biopharmaceutics Review(s), Application Number 22-465</i> , Center for Drug Evaluation & Research (2009) (“No. 22-465”)	X
2131	Eylea HD® Highlights of Prescribing Information (Apr. 2026)	X
2132	U.S. Food & Drug Admin., <i>April 2018: Inactive Ingredient Database File</i> , downloaded from https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download (last visited June 17, 2026) (“Inactive Ingredient Database”)	X
2133	Excerpt from T.V. Chirila, et al., <i>The Vitreous Humor</i> , Handbook of Biological Properties, 125 (1998) (“Chirila”)	X
2134	Mohab Eldeeb, et al., <i>One-Year Outcomes of Ziv-Aflibercept for Macular Edema in Central Retinal Vein Occlusion</i> , 8 Am. J. Ophthalmology Case Reports 58 (2017) (“Eldeeb”)	X

Exhibit	Description	Filed
2135	Tetsuo Hida, <i>Experimental and Clinical Observations of the Intraocular Toxicity of Commercial Cortiosteroid Preparations</i> , 101 Am. J. Ophthalmology 190 (1986) (“Hida”)	X
2136	J. García-Carmona, <i>Morphological Characteristics and Aggregation of Calcite Crystals Obtained by Bubbling CO₂ through a Ca(OH)₂ Suspension in the Presence of Additives</i> , 130 Powder Tech. 307 (2003) (“García-Carmona”)	X
2137	E.N. Lee et al., <i>Stabilizing Peptide Fusion for Solving the Stability and Solubility Problems of Therapeutic Proteins</i> , 22 Pharm. Res. 1735, 1745 (2005) (“Lee”)	X
2138	J.F. Carpenter et al., <i>Rational Design of Stable Lyophilized Protein Formulations: Theory and Practice</i> , in Rational Design of Stable Protein Formulations 109, 109 (J.F. Carpenter & M.C. Manning eds., 2002) (“Carpenter”)	X
2139	Biochemistry: A Problems Approach, Chapter 2: Amino Acids (2d ed. 1981) (“Biochemistry”)	X
2140	U. Schmidt-Erfurth et al., <i>Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration</i> , 121 Ophthalmology 193 (2014)	X
2141	Regeneron, Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration, Regeneron Press Release Details, (Aug. 24, 2021), https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-topline-phase-2-data-high-dose	X
2142	Marina Gühlike, <i>Taking Subvisible Particle Quantitation to the Limit</i> , 109 J. Pharm. Sci. 505 (2020) (“Gühlike”)	X

Exhibit	Description	Filed
2143	J.G. Gross, <i>Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy</i> , 135 JAMA Ophthalmology 672 (2017)	X
2144	2026.06.09 Email from M. Chacon	X
2145	2025.09.17 Email from Dr. D'Amico	X
2146	Declaration of Mark Hudson	

Dated: July 13, 2026

Respectfully submitted,

/David I. Berl/

David I. Berl
Reg. No. 72,751
Williams & Connolly LLP
680 Maine Avenue SW
Washington, D.C. 20024
Lead Counsel for Patent Owner

CERTIFICATE OF SERVICE
(37 C.F.R. § 42.6(e))

The undersigned hereby certifies that on July 13, 2026, I caused true and correct copies of the foregoing and Exhibit 2146 to be served via e-mail on the following:

Name	E-Mail Address
Martina Hufnal	PGR46514-0017PS1@fr.com
Michael Kane	PGR46514-0017PS1@fr.com
Kristi L. R. Sawert	PGR46514-0017PS1@fr.com
Nitika Fiorella	PGR46514-0017PS1@fr.com
Megan A. Chacon	PGR46514-0017PS1@fr.com
Deanna Reichel	PGR46514-0017PS1@fr.com
Phillip Chen	PGR46514-0017PS1@fr.com

Date: July 13, 2026

/David I. Berl/

David I. Berl

Reg. No. 72,751

Lead Counsel for Patent Owner